Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TISLELIZUMAB Cause Hepatic function abnormal? 221 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 221 reports of Hepatic function abnormal have been filed in association with TISLELIZUMAB (TEVIMBRA). This represents 4.4% of all adverse event reports for TISLELIZUMAB.

221
Reports of Hepatic function abnormal with TISLELIZUMAB
4.4%
of all TISLELIZUMAB reports
1
Deaths
144
Hospitalizations

How Dangerous Is Hepatic function abnormal From TISLELIZUMAB?

Of the 221 reports, 1 (0.5%) resulted in death, 144 (65.2%) required hospitalization, and 3 (1.4%) were considered life-threatening.

Is Hepatic function abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TISLELIZUMAB. However, 221 reports have been filed with the FAERS database.

What Other Side Effects Does TISLELIZUMAB Cause?

Myelosuppression (2,142) White blood cell count decreased (327) Neutrophil count decreased (277) Pruritus (213) Rash (208) Platelet count decreased (183) Pyrexia (175) Nausea (165) Diarrhoea (145) Liver injury (139)

What Other Drugs Cause Hepatic function abnormal?

NIVOLUMAB (1,131) PEMBROLIZUMAB (1,079) METHOTREXATE (1,054) CABOZANTINIB S-MALATE (912) CYCLOPHOSPHAMIDE (824) BEVACIZUMAB (769) PACLITAXEL (603) LENVATINIB (528) ATORVASTATIN (520) CYCLOSPORINE (508)

Which TISLELIZUMAB Alternatives Have Lower Hepatic function abnormal Risk?

TISLELIZUMAB vs TISOTUMAB VEDOTIN TISLELIZUMAB vs TISOTUMAB VEDOTIN-TFTV TISLELIZUMAB vs TITANIUM DIOXIDE\ZINC TISLELIZUMAB vs TIVICAY TISLELIZUMAB vs TIVOZANIB

Related Pages

TISLELIZUMAB Full Profile All Hepatic function abnormal Reports All Drugs Causing Hepatic function abnormal TISLELIZUMAB Demographics